Taxonomy

CMTA and Applied Therapeutics Announce Collaboration for CMT-SORD

CMTA and Applied Therapeutics Announce Collaboration for CMT-SORD (Glenolden, PA,

Taysha Gene Therapies & CMTA Collaborate to Increase Genetic Testing Access for Giant Axonal Neuropathy (GAN)

Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal

CMTA and ToolGen Announce CMT1A Collaboration

CMTA and ToolGen Announce Collaboration to Develop Potential Treatment for

CMTA and Addex Announce CMT1A Collaboration

CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B

CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials

CMTA-STAR announced $1.1 million in grants March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2A

CMTA and Pharnext Enter Biomarker Research Collaboration

Collaboration focused on identifying and characterizing key biomarkers in Charcot-Marie-Tooth disease Type 1A

Type 2 Update: One Patient’s Diagnostic Odyssey with SORD

In "A Diagnosis Worthy of a Tattoo," CMT patient and champion fundraiser Vittorio Ricci describes how he was finally diagnosed after six years and several trips to the CMTA Center of Excellence headed by Dr. Michael Shy.

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) This study is

Research Survey About Impacts of COVID‑19

Rare disease patients and caregivers: How are you being impacted

New, Potentially Treatable, Type of CMT Discovered

A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases.